Medical University of Vienna-ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2023

  1. New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 9, Núm. 4, pp. 353-370

2022

  1. Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 1, pp. 100-103

  2. Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 4, pp. 406-419

  3. Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 2, pp. 187-210

  4. Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 8, Núm. 3, pp. 302-310

  5. The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European heart journal. Cardiovascular pharmacotherapy, Vol. 8, Núm. 1, pp. 85-99

2021

  1. The age of randomized clinical trials: Three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 7, Núm. 5, pp. 453-459

  2. Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: A review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 7, Núm. 6, pp. 557-567

2020

  1. Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: Systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 6, Núm. 2, pp. 86-93

  2. Lipid management in rheumatoid arthritis: A position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 6, Núm. 2, pp. 104-114

2019

  1. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: Systematic review and meta-analysis

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 5, Núm. 4, pp. 226-236

  2. Oral Anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1

    European Heart Journal, Vol. 40, Núm. 36, pp. 3010-3012

  3. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: A current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 5, Núm. 3, pp. 171-180

2018

  1. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: Coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 4, Núm. 3, pp. 180-188

  2. Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

    European Heart Journal, Vol. 39, Núm. 24, pp. 2274-2281

  3. Reasons for disparity in statin adherence rates between clinical trials and real-world observations: A review

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 4, Núm. 4, pp. 230-236

2017

  1. Comprehensive efforts to increase adherence to statin therapy

    European Heart Journal, Vol. 38, Núm. 32, pp. 2473-2477

  2. Gender differences in the effects of cardiovascular drugs

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 3, Núm. 3, pp. 163-182

  3. Reversal strategies for non-Vitamin K antagonist oral anticoagulants: A critical appraisal of available evidence and recommendations for clinical management - A joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis

    European Heart Journal, Vol. 38, Núm. 22, pp. 1710-1716

2016

  1. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: Review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 2, Núm. 2, pp. 108-118